Ropes & Gray represented Sarepta Therapeutics, Inc. in its privately negotiated exchange of approximately $291.4 million aggregate principal amount of its 1.25% convertible senior notes due 2027 for new 4.875% convertible senior notes due 2030 and cash. The exchange was announced on December 11 and closed on December 18.
Sarepta Therapeutics is a leader in precision genetic medicine for rare diseases, focused on developing transformative therapies for patients with unmet medical needs.
The Ropes & Gray team was led by capital markets partner Will Michener and included tax partner David Saltzman.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.